Opinion|Videos|July 22, 2024
Navigating Treatment Approaches for R/R CLL
A clinician outlines their treatment strategy for relapsed/refractory chronic lymphocytic leukemia patients, emphasizing how previous treatment history influences subsequent therapy choices.
Advertisement
Episodes in this series
- What is your general treatment approach in patients with R/R CLL?
- How does prior 1L therapy influence your treatment decision?
- In what clinical scenarios may you consider a non-covalent BTKi for patients with R/R CLL?
Advertisement
Related to this article
Lisaftoclax plus acalabrutinib earned breakthrough therapy status in China for untreated CLL/SLL.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
The top 5 OncLive TV videos of the week.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Full Approval to Pembrolizumab for Unresectable/Metastatic TMB-H Solid Tumors
2
HER2+ mCRC Treatment Sequencing Favors Tucatinib Plus Trastuzumab Before T-DXd
3
Polls Reveal Top Picks for Lung Cancer Abstracts of Interest at ESMO 2026
4
Poll Results Highlight Gynecologic Cancer Abstracts of Interest at ESMO 2026
5